The Effects Of Placebo Treatment On Patient Condition

1911 Words Oct 10th, 2016 8 Pages
SLEDAI has been shown to be reliable and reproducible when used by various investigators, and sensitive to change in patient condition but it doesn 't measure worsening of an already existing sign or symptom, nor does it detect partial improvement if some degree of residual symptom remains. Both of these limits might contribute in narrowing the gap between the observed effects of placebo treatment and that of a potentially useful medication. The SLEDAI also doesn 't account for subjective symptoms like fatigue, dysphoria, arthralgia or myalgia, which might genuinely reflect lupus activity, and may be of high importance to patients (Fortin et al. 2000; E. Chang et al. 2002).
An update version SLEDAI-2000 (SLEDAI-2k) was introduced and validated in 2002 based on findings in the preceding 10 days. SLEDAI-2k allow the documentation of ongoing disease activity in the descriptor s skin rash, alopecia, mucosal ulcers and proteinuria as opposed to only new occurrence as defined in the original SLEDAI (Gladman et al. 2002). SLEDAI-2k was validated against the original SLEDAI and shown to describe disease activity at various activity levels in a comparable manner to the original SLEDAI (Gladmann et al. 2002).

Table (2):Systemic Lupus Erythematosus Disease Activity Index (SLEDAI).
Wtd
score
Descriptor
Definition.
8
Seizure
Recent onset. Exclude metabolic, infectious, or drug-related causes.
8
Psychosis
Altered ability to function in normal activity due to severe disturbance in the…
Open Document